中国全科医学2017，Vol.20Issue(2)：232-236,5.DOI:10.3969/j.issn.1007-9572.2017.02.023
间变性淋巴瘤激酶融合基因阳性的非小细胞肺癌的治疗进展
Progress in the Treatment for Anaplastic Lymphoma Kinase Fusion Gene Positive in Non-small Cell Lung Cancer
摘要
Abstract
Molecular targeted therapy has become an important therapeutic modality for non - small cell lung cancer (NSCLC). Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)have been reported to exert a significant impact in the treatment of NSCLC. However,patients eventually develop drug resistance to EGFR-TKIs. Recently,anaplastic lymphoma kinase( ALK)fusion gene has been described as important driver gene in a subset of patients with NSCLC and becomes the new targets for NSCLC treatment. This paper reviewed the ALK fusion gene and progress of ALK inhibitors for the treatment of ALK fusion gene positive NSCLC patients.关键词
癌,非小细胞肺/分子靶向治疗/间变性淋巴瘤激酶/基因融合Key words
Carcinoma,non - small - cell lung/Molecular targeted therapy/Anaplastic lymphoma kinase/Gene fusion分类
医药卫生引用本文复制引用
胡萍,张运剑..间变性淋巴瘤激酶融合基因阳性的非小细胞肺癌的治疗进展[J].中国全科医学,2017,20(2):232-236,5.基金项目
国家自然科学基金资助项目（91543124）；北京市科学技术委员会资助课题 （）
